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A B S T R A C T
An octogenarian on double clopidogrel maintenance dose (150 mg qd), due to clopi-
dogrel resistance determined with a point-of-care assay, was subjected to percutane-
ous coronary intervention (PCI) of the left anterior descending coronary artery with 
two drug eluting stents. Twenty-four hours later the patient sustained subacute stent 
thrombosis manifesting as an anterior ST-elevation myocardial infarction with car-
diogenic shock. Optical coherence tomography disclosed thrombus inside the stent 
without malapposition. Thrombus aspiration and balloon inflation of the thrombosed 
stent restored vessel patency. The issue of clopidogrel resistance and methods to over-
come it are discussed.
I n T R o d u C T I o n
Subacute stent thrombosis with resultant abrupt vessel closure is one of the most 
common early complications of percutaneous coronary intervention (PCI), with dire 
consequences as it leads to high rate of Q-wave myocardial infarction (MI) and death. 
Subacute vessel occlusion was initially ascribed to increased stent thrombogenicity 
and inadequate antithrombotic therapy, and indeed since these regimens were opti-
mized, the incidence of subacute stent thrombosis dropped to levels < 2%.1 However, 
it still constitutes a major cause of death after PCI, despite the improvement noted 
in antiplatelet therapy, although the main cause nowadays appears to be suboptimal 
final results of stent implantation (e.g. stent under-deployment). This notwithstanding, 
resistance to antiplatelet therapy also seems to play an important role in this complica-
tion, 2-6 as will be shown in the present case.
C A S e  R e p o R T
An 83-year-old male was transferred from a district hospital to our tertiary center 
for primary angioplasty due to an acute lateral wall MI. Time from symptom onset was 
3 hours and transfer time was 45 minutes. Aspirin (325 mg) and a clopidogrel loading 
dose (600 mg) were administered at the referring hospital, along with 5000 IU of un-
fractionated heparin. Coronary angiography from a right femoral approach disclosed 
total occlusion of the first marginal branch of the left circumflex artery (LCX), and 
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AbbreviAtions
DES = drug eluting stent(s)
MI = myocardial infarction
OCT = optical coherence tomography
PCI = percutaneous coronary intervention
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two 80-90% stenoses of the left anterior descending coronary 
artery (LAD) (Figure 1). A second bolus of unfractionated 
heparin (5000 IU) was administered at the catheterization 
laboratory. The total occlusion of the LCX was crossed 
with a guidewire and thrombus aspiration followed. After 
intravenous administration of standard abciximab loading, 
balloon angioplasty with a 2/15 mm balloon was performed 
and two overlapping paclitaxel drug eluting stents (DES) 
(PhoenixPicoTM, Saudi Health Services Co. LTD, Jeddah, Saudi 
Arabia, 2.75/19 and 2.75/8 mm), were implanted successfully, 
followed by post-stenting inflation of a non-compliant bal-
loon of the same size, restoring a TIMI-3 flow (Figure 1). 
The chest pain and ST-elevation resolved. The patient was 
transferred to the coronary care unit and had an uneventful 
course. Administration of aspirin 325 mg qd and clopidogrel 
75 mg qd was continued for 24 hours, when in the context of 
a research protocol, post-clopidogrel platelet reactivity was 
measured with a point of care assay device (VerifyNow P2Y12 
assay, Accumetrics Inc., San Diego, CA, USA). The latter was 
found to be 339 platelet reactivity units (PRU). With a cut-off 
value of 230 PRU for clopidogrel resistance the patient was 
considered resistant, and in the context of a research protocol 
following informed consent, he was randomized to a double 
clopidogrel maintenance dose (150 mg qd), in addition to 
aspirin 325 mg qd. The patient was also on statin, angiotensin 
converting enzyme inhibitor and beta-blocker therapy.
On the third post-MI day, the LAD lesions were treated 
successfully via a left femoral approach, with two paclitaxel 
DES (Infinium, Sahajanand Medical Technologies Pvt Ltd., 
Gujarat, India, 3/18 and 2.75/18 mm respectively), followed 
by post-stenting inflation of a non-compliant balloon of the 
same size (Figure 2). No further platelet glycoprotein IIb/IIIa 
inhibitor therapy was administered during the second PCI. On 
the next day the patient was transferred to the referring hos-
pital. Twenty four hours following the LAD angioplasty, the 
patient sustained a new anterior acute MI with signs of acute 
pulmonary edema and was transferred back to our center for 
emergency coronary angiography. The latter was performed 
via a right femoral approach and disclosed thrombosis of the 
2.75/18 mm DES with total occlusion of the LAD and throm-
bus extending up to the proximal DES (Figure 3). Thrombus 
aspiration was successfully performed and optical coherence 
tomography (OCT) imaging disclosed thrombus without 
malapposition of the two DES (Figure 4). Due to signs of 
cardiogenic shock with a blood pressure of 65/30 mmHg and 
patient confusion, an intra-aortic balloon was placed via the 
left femoral artery. Subsequently, balloon angioplasty with a 
3/15 mm non-compliant balloon was performed in the two 
DES, with restoration of vessel patency and a TIMI-2 flow 
(Figure 3). The patient was initially stabilized and transferred 
to the coronary care unit. However, two days later the patient 
developed acute renal failure and signs of cardiogenic shock 
despite balloon counterpulsation and infusion of dobutamine 
FIguRe 1. Coronary angiography during primary angioplasty. 
On the left, the totally occluded obtuse marginal branch is de-
picted (white arrow). On the right, vessel patency has been re-
stored post-stenting with two overlapping DES (2.75/19, 2.75/8 
mm). The two white arrows point to the LAD stenoses. LAD = 
left anterior descending artery, DES = drug eluting stent.
FIguRe 2. Coronary angiography during angioplasty of the 
LAD. On the left, the two white arrows point to the LAD sten-
oses. On the right, vessel patency has been restored post-stent-
ing with two DES (2.75/18 mm for the distal lesion and 3/18 mm 
for the proximal lesion). LAD = left anterior descending artery, 
DES = drug eluting stent.
FIguRe 3. Coronary angiography. On the left, the white arrow 
points to the thrombosed LAD stent (2.75/18 mm). On the right, 
following thrombus aspiration and plain balloon angioplasty 
with a non-compliant 2.75/15 mm balloon, vessel patency has 
been restored. LAD = left anterior descending artery.
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and dopamine, and eventually succumbed.
d I S C u S S I o n
This case illustrates that subacute stent thrombosis may 
occur despite doubling of clopidogrel maintenance dose in 
patients considered to be clopidogrel resistant. On the other 
hand we should not underestimate the role of local condi-
tions post-procedure (residual stenosis, dissection, non-op-
timal stent apposition, etc.) in providing the milieu for stent 
thrombosis.1
Clopidogrel resistance may be defined as clinical, i.e. ongo-
ing thrombotic events despite clopidogrel therapy, or labora-
tory based on results of platelet function tests. The relative 
inhibition of platelet aggregation between pre-treatment and 
post-treatment is the most common estimate of clopidogrel 
responsiveness, however, patients responsive to clopidogrel 
may remain with highly reactive platelets and thus have in-
creased thrombotic risk. It has been shown that assessment 
of clopidogrel responsiveness may be less clinically relevant 
compared to assessment of post-treatment platelet function 
as the latter is a better predictor of ischemic events.2 Platelet 
function can be assessed ex-vivo with various methods, and 
the incidence of clopidogrel resistance reported lies between 5 
and 44% depending on the population studied, the laboratory 
method used and the pre-specified cut-off values for defining 
clopidogrel resistance.3-5 Although the reported incidence 
of clopidogrel resistance as determined with ex-vivo platelet 
reactivity assessment is high, the incidence of post-PCI clinical 
events is low (5-10%). This has raised concerns regarding the 
clinical relevance of such kind of assessment, however there 
is a lot of accumulating evidence that ex-vivo platelet function 
testing is associated with clinical events. 3,6-10
Light transmitter aggregometry remains the gold standard 
for assessment of clopidogrel resistance, however it is neither 
widely available nor cost effective. Clopidogrel resistance de-
termined with light transmittance aggregometry is associated 
with a high incidence of definite or probable stent thrombosis 
(up to 3 times higher compared to non-resistant patients), one 
year following PCI with DES.11 Point-of-care assay devices 
(VerifyNow P2Y12 assay, Accumetrics Inc., San Diego, CA, 
USA) are now available and platelet reactivity is measured at 
the bedside in a few minutes. Platelet reactivity assessed with 
the latter is reported in platelet reactivity units (PRU), and 
post-treatment values above a certain limit define clopidogrel 
resistance. Obviously the higher the pre-specified cut-off value 
of PRU used for defining clopidogrel resistance, the less the 
incidence of the latter. High post-treatment platelet reactiv-
ity measured with a point-of-care platelet function assay was 
found to be associated with stent thrombosis post- PCI with 
DES.12
Various treatment strategies to reduce ischemic complica-
tions post-PCI and/or overcome clopidogrel resistance have 
been proposed, among which doubling the maintenance dose 
of clopidogrel (from 75 to 150 mg qd),13 co-administration of 
IIb-IIIa inhibitors for resistant patients,14 or switching to newer 
anti-platelet agents like prasugrel or ticagrelor. The CUR-
RENT OASIS-7 study showed that doubling the loading dose 
of clopidogrel and administering a double maintenance dose 
(150 mg) for 7 days in patients with acute coronary syndromes 
undergoing planned PCI, significantly reduced stent throm-
FIguRe 4. Three successive optical coherence tomography (OCT) images acquired following thrombus aspiration of the LAD. 
Panel-A acquired at the level of the thrombosed 2.75/18 mm DES, shows high-backscattering protrusions inside the lumen of the 
artery corresponding to red thrombus (closed white arrow). The open arrow points to a stent strut. Panel-b acquired between the 2 
DES of the LAD, shows signal-rich concentric fibrous plaque with a lipid pool (L), at 12 o clock. Panel-C acquired at the level of the 
proximal LAD stent (3/18 mm), shows high-backscattering protrusions with signal-free shadowing corresponding to red thrombus 




bosis and cardiovascular events, largely driven by reductions 
in MI, without a significant increase in major bleeding.15 We 
could speculate that this may in part be due to overcoming of 
the hypothetical clopidogrel resistance that might exist in some 
of the studied patients, by the higher dose. If this is correct, 
then screening for clopidogrel resistance in the catheterization 
laboratory, or post-PCI with a point-of-care device might be 
used routinely to recognize those patients that may benefit 
from a higher clopidogrel maintenance dose. However, our 
case exemplifies the fact that doubling the maintenance dose 
of clopidogrel in patients with clopidogrel resistance, may not 
be enough for reducing ischemic complications post-PCI with 
stenting. The 3T study showed that in aspirin, clopidogrel, or 
dual poor responder patients (detected with a point-of-care 
assay), with low-risk unstable coronary artery disease under-
going elective PCI, administration of tirofiban in addition to 
standard aspirin and clopidogrel therapy, lowers the incidence 
of post-PCI MI.14 This concept needs further studying. Our 
patient had received abciximab during the primary PCI of the 
LCX, however a second administration of a IIb/IIIa inhibitor 
during PCI of the LAD was judged as potentially harmful 
by the interventionalist in an octogenarian being already on 
aspirin 325 mg and clopidogrel 150 mg qd.
Prasugrel, a potent and rapid-acting thienopyridine, is a 
potential alternative to clopidogrel. The recent TRITON-
TIMI 38 study showed that in patients with ST-elevation MI 
undergoing PCI, prasugrel is more effective than standard 
clopidogrel for prevention of ischemic events, without an 
apparent excess in bleeding, apart from an increase in TIMI 
major bleeding after coronary bypass surgery.16 In addition, 
the TRITON-TIMI 38 platelet sub-study demonstrated that 
prasugrel results in greater inhibition of ADP-mediated 
platelet function in patients with acute coronary syndrome 
than clopidogrel.17 This finding also supports the hypothesis 
that greater platelet inhibition leads to a lower incidence of 
ischemic events with the cost of more bleeding both early and 
late following PCI. It is not known if the above results apply 
to the comparison between standard prasugrel treatment 
and double clopidogrel dose treatment, especially in patients 
resistant to standard clopidogrel treatment. Our patient 
was not switched to prasugrel treatment when clopidogrel 
resistance was diagnosed, as prasugrel is contra-indicated in 
octogenarians.
Apart from patient/physician non-compliance to clopi-
dogrel treatment, real clopidogrel resistance is thought to be 
related to drug metabolism and biotransformation. Clopidog-
rel requires transformation into an active metabolite by cyto-
chrome P-450 (CYP) enzymes for its antiplatelet effect. The 
genes encoding CYP enzymes are polymorphic, with common 
alleles conferring reduced function. In healthy subjects treated 
with clopidogrel, carriers of at least one CYP2C19 reduced-
function allele had a relative reduction of 32.4% in plasma 
exposure to the active metabolite of clopidogrel, as compared 
with non-carriers, and an absolute reduction in maximal 
platelet aggregation in response to clopidogrel 9 percentage 
points less than that seen in noncarriers.18 Among clopidogrel-
treated subjects in TRITON-TIMI 38, carriers had a relative 
increase of 53% in the composite primary efficacy outcome 
of the risk of death from cardiovascular causes, MI, or stroke, 
compared with non-carriers and a 3-fold increase in the risk 
of stent thrombosis.18 Ticagrelor is a novel oral, reversible, 
direct-acting inhibitor of the ADP receptor P2Y12, that has 
a more rapid onset and more pronounced platelet inhibition 
than clopidogrel. The recently published PLATO study showed 
that ticagrelor (180-mg loading dose, 90 mg bid thereafter), 
compared to standard clopidogrel treatment (300-to-600-
mg loading dose, 75 mg daily thereafter), in patients with or 
without ST-segment elevation acute coronary syndromes, 
significantly reduced the rate of death from vascular causes, 
MI, or stroke without an increase in the rate of overall major 
bleeding but with an increase in the rate of non-procedure-
related bleeding.18 It may be that drugs like ticagrelor, which 
theoretically by-pass the principal mechanisms of clopidogrel 
resistance, will be the answer to this issue at least for some 
patients, however this remains to be proved.
L I m I T A T I o n S
There are no guidelines regarding management of pa-
tients considered resistant to clopidogrel. Doubling of the 
clopidogrel maintenance dose in the above case, was done 
in the context of a research protocol and following patient’s 
informed consent. This case exemplifies the fact that until 
randomized studies definitively show that a certain strategy 
or drug is recommended or preferred for such patients, car-
diologists should be very cautious and more conservative and 
prudent regarding further management. The latter applies to 
our choice to proceed to LAD stenting very soon following 
the index procedure. Although this is the current practice 
in our center for all patients with multivessel disease follow-
ing primary PCI, current guidelines advise otherwise, i.e. 
performing PCI of the culprit lesion only while postponing 
further revascularization for later on with staged elective 
procedures.20-22 Only in the setting of cardiogenic shock there 
is consensus for attempting multivessel PCI.
The usage of two kinds of stents in the two procedures 
raises the issue of potential hypersensitivity reaction, which 
might have contributed to inflammation and thrombosis. 
However, there is no convincing evidence that this might 
have happened as systemic hypersensitivity symptoms and 
signs were absent in our patient, and the 2 DES used elute 
the same drug (paclitaxel). Alternatively, local hypersensitivity 
may be a tempting theory, but this has not been proved, and 
most reported hypersensitivity reactions to DES are either 
accompanied by systemic reactions, or happen late or very 
late post-stenting.23-25 Usage of the same kind of DES with 
the same structure, polymer and eluted drug may be safer in 
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staged procedures; however this needs to be proved.
C o n C L u S I o n
Laboratory clopidogrel resistance is associated with clini-
cal resistance in some patients, with catastrophic consequences 
post-PCI with stenting. Doubling the standard clopidogrel 
maintenance dose of 75 mg in such patients may not be enough 
to overcome clinical resistance.
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